The disclosure relates to a method for manufacturing a mold for a cardiac valve prosthesis, a computer program product and to a mold for a cardiac valve prosthesis.
In prior art, cardiac valve replacement by mechanical and biological cardiac valves is known.
Cardiac valve replacement using mechanical cardiac valves is established since the 1960s. Synthetically manufactured prostheses made from metal or plastic (polymers) are implanted to a patient in an open-heart surgery by use of cardiopulmonary bypass. The disadvantage of this procedure is the necessity of a lifelong anticoagulation therapy to avoid the formation of thrombi on the foreign surface of the prostheses. On the other hand, an advantage is the theoretic lifelong durability of the prosthetic cardiac valve. Therefore, it is mostly used for young adults. Female patients who want to give birth are mostly excluded from this therapy so far.
Biological cardiac valves are mostly produced from bovine or porcine pericardium or consist of whole bovine or porcine cardiac valves. In addition, bovine jugular vein valves are used as cardiac valve prostheses. Valves from animal tissue are called xenogenic. They either are implanted surgically or, since around year 2000, are implanted by cardiac catheter interventions as stented cardiac valves.
Further, biological cardiac valves can be harvested from human valve donors (allografts) or in some cases from the patient herself/himself for use as an autograft (e.g. in the so called ROSS procedure).
The advantage in using biological materials is avoidance of long-term anticoagulation therapy. The disadvantage, however, is that—apart from autografts—these cardiac valves are eventually rejected due to an immune reaction since they originate from a foreign source. This rejection often occurs even though a multistep pretreatment is performed to reduce the risk of an immune reaction. The result of such an immune reaction is degradation of the implanted cardiac valve. Therefore, the durability of biological cardiac valves—especially xenografts—is limited to approximately 5 to 15 years. Afterwards, another cardiac valve replacement is necessary.
The advantage of valves of human origin is a longer durability due to a lower immune response. The main disadvantage is, however, that these valves are increasingly difficult to obtain since the willingness for donations decreases. A special case is the self-donation: By an operation called ROSS procedure, the own (autologous) pulmonary valve is implanted instead of the diseased aortic valve, wherein the missing pulmonary valve is then replaced by a xeno- or allograft referred to above.
As already mentioned, cardiac valve prostheses can be implanted by a surgical or an interventional or a hybrid procedure (combining surgical and interventional techniques). A replacement by an interventional transcutaneous procedure is based on the use of catheters and the modified Seldinger technique. The intervention can be subdivided into a transvenous, transarterial, and a transapical intervention. The transapical access is established through the thoracic wall and the cardiac apex into the left or right ventricle. In case of the transvenous access, the right part of the heart with its valves is reached antegradely (i.e., with the bloodstream). After puncture of the atrial septum, also the left part of the heart can be reached. By the transarterial approach the left heart chambers and valves can be reached retrogradely.
It is an object underlying the proposed solution to provide methods and devices that facilitate the manufacture of cardiac valve prostheses that combine a long durability and a low disposition for the formation of thrombi on their surface.
This object is achieved with a method for manufacturing a mold for a cardiac valve prosthesis having features as described herein. This method comprises the steps explained in the following.
First, 3-D imaging data of an impaired cardiac valve of an individual is provided. Thereby, this imaging data has been obtained by an appropriate imaging method prior to carrying out the claimed method. Appropriate methods are, e.g., magnetic resonance imaging (MRI), computed tomography (CT), (3-D) ultrasound (e.g., echocardiography), or 3-D rotational angiography.
Afterwards, the 3-D imaging data is reconstructed in a three-dimensional manner Thereby, impairments of the impaired cardiac valve are at least partially corrected (so-called virtual valve surgery). As a result, reconstructed 3-D imaging data is obtained that represents a virtual cardiac valve. This virtual cardiac valve has a performance that better corresponds to the performance of a non-impaired cardiac valve than the performance of the impaired cardiac valve does. The term “performance” is in particular to be understood as the ability to open and close in a cardiac blood vessel or heart chamber. Thus, the cardiac valve having a good performance has a good ability to open and close in a cardiac blood vessel or heart chamber.
Subsequently, the reconstructed 3-D imaging data is used to generate a virtual 3-D mold for a cardiac valve prosthesis. Since the reconstructed 3-D imaging data is based on imaging data of a specific individual, the virtual 3-D mold is a mold for an individually personalized cardiac valve prosthesis.
Finally, the virtual 3-D mold is used to manufacture a real mold for a cardiac valve prosthesis. To be more precise, it is used to manufacture a real mold for an individually personalized cardiac valve prosthesis.
This real mold for an individually personalized cardiac valve prosthesis can then be used to manufacture an individually personalized cardiac valve prosthesis. This can be done, e.g., by applying any desired material into the real mold and to give the inserted material the shape of the real mold, e.g., by applying positive or negative pressure, suction or vacuum, temperature changes and/or biochemically active substances such as cross-linkers. To give an example, body tissue of the human or animal in need of obtaining an individually personalized cardiac valve prosthesis can be used for being re-shaped within the real mold as to obtain an individually personalized cardiac valve prosthesis.
In an aspect, the solution relates to a method that also encompasses a method step for obtaining 3-D imaging data of an impaired cardiac valve of an individual by an appropriate imaging method.
In an embodiment, the performance of the virtual cardiac valve that is represented by the reconstructed 3-D imaging data is tested by simulation after the step of 3-D reconstructing the 3-D imaging data. This simulation is done in terms of systolic and diastolic flow and/or vortices and/or streamlines and/or pressure fields and/or a pressure gradient across the virtual cardiac valve. By such a simulation, the performance of the virtual cardiac valve can be assessed in more detail in order to ensure that the virtual cardiac valve has indeed a better performance than the impaired cardiac valve that is to be replaced. The simulation of the performance of the virtual cardiac valve can best be done by specialized software.
In an embodiment, the 3-D imaging data is the 3-D imaging data of an impaired human cardiac valve.
In an embodiment, the 3-D imaging data is the 3-D imaging data of an impaired animal valve. The animal is, in an embodiment, a rodent or a non-human mammal.
In an embodiment, the step of 3-D reconstruction of the 3-D imaging data comprises a step in which at least one impaired or diseased area of the impaired cardiac valve is virtually excised (so-called virtual valve surgery). Furthermore, the excised area is then replaced by a remodeled area having an appearance of healthy tissue, in particular of healthy cardiac tissue. Then, the reconstructed 3-D imaging data resembles or corresponds to a non-impaired cardiac valve.
While it is generally possible to manufacture the real mold for an individually personalized cardiac valve prosthesis by any appropriate manufacturing method, this step is done, in an embodiment, by injection molding or by 3-D printing. 3-D printing is particular appropriate since it allows for manufacturing individually personalized molds at particularly low cost and high speed.
The real mold for an individually personalized cardiac valve prosthesis can be used to manufacture any kind of cardiac valve prosthesis. Hence, it is, in an embodiment, a mold for an aortic valve prosthesis. In another embodiment, it is a mold for a pulmonary valve prosthesis. In another embodiment, it is a mold for a mitral valve prosthesis. In another embodiment, it is a mold for a tricuspid valve prosthesis.
In an aspect, the solution also relates to a (non-transitory) computer program product comprising a software with executable code that causes a computer to perform the steps explained in the following upon being executed on the computer. First, provided 3-D imaging data of an impaired cardiac valve of an individual is automatically 3-D reconstructed. Thereby, impairments of the impaired cardiac valve are at least partially corrected. This results in reconstructed 3-D imaging data representing a virtual cardiac valve having a performance that better corresponds to the performance of a non-impaired cardiac valve than the performance of the impaired cardiac valve does.
Furthermore, the computer program causes the computer to automatically use the reconstructed 3-D imaging data to generate a virtual 3-D mold for a cardiac valve prosthesis.
In an embodiment, the software causes the computer additionally to automatically control the manufacturing of a real mold for an individually personalized cardiac prosthesis on the basis of the virtual 3-D mold. Thus, the computer program can control, e.g., a 3-D printer to manufacture a real mold for an individually personalized cardiac valve prosthesis.
In an embodiment, the software causes the computer to perform an additional step prior to automatically generating a virtual 3-D mold for a cardiac valve prosthesis, namely a step of simulating the performance of the virtual cardiac valve in terms of systolic and diastolic flow and/or vortices and/or streamlines and/or pressure fields and/or a pressure gradient across the virtual cardiac valve.
In an aspect, the solution also relates to a mold for an individually personalized cardiac valve prosthesis that is or can be obtained by a method according to the preceding explanations.
All embodiments of the described method can be combined in any desired way and can be transferred either individually or in any arbitrary combination to the described computer program product and the described mold for an individually personalized cardiac valve prosthesis, and vice versa.
Further details of aspects of the solution will be explained in the following with respect to exemplary embodiments and accompanying Figures.
In a second step 110, the 3-D imaging data is reconstructed. This second step 110 can also be denoted as virtual cardiac valve surgery. By this step, a detected impairment of the human cardiac valve from which the 3-D imaging data was obtained is virtually corrected. This impairment typically results in a more or less pronounced dysfunction of the human cardiac valve. When performing the virtual cardiac valve surgery 110, the according impairment is virtually correct. Thus, reconstructed 3-D imaging data results that represents a human cardiac valve having better functional properties than the human cardiac valve from which the 3-D imaging data was obtained. Expressed in other words, the cardiac valve of the reconstructed 3-D imaging data has a better functionality than the original cardiac valve from which the 3-D imaging data has been obtained.
In a third step 120, the reconstructed 3-D imaging data is used for generating a virtual 3-D mold for a personalized cardiac valve prosthesis.
Subsequently, the virtual 3-D mold is used in a fourth step 130 to manufacture a real mold for a cardiac valve prosthesis. This real mold will then serve for manufacturing a cardiac valve prosthesis having better properties than the cardiac valve from which the 3-D imaging data has been obtained.
The individual steps of manufacturing a cardiac valve prosthesis with the help of the first part 1 and the second part 2 of the mold will be explained in the following in more detail making reference to
As shown in
As shown in a top view in
As shown in
The reaction container 6 comprises an inlet port 11 and an outlet port 12. A reaction liquid can be fed into the reaction container 6 through the inlet port 11 and can be drained from an interior of the reaction container 6 by the outlet 12.
In the embodiment shown in
Number | Date | Country | Kind |
---|---|---|---|
20213219.7 | Dec 2020 | EP | regional |
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/EP2021/085101 | 12/9/2021 | WO |